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GUEST EDITORIAL
Illicit drugs and seizuresThe use of recreational illicit drugs and other psy-
choactive substances has become commonplace, par-
ticularly among teenagers1. It is therefore surprising
how little is known of their long-term psychological
and cognitive effects, their influence on specific neu-
rological conditions such as epilepsy, and their interac-
tion with antiepileptic medications. Their use is suffi-
ciently widespread for many young patients presenting
with seizures to have had some experience of recre-
ational drugs. Occasionally, patients on antiepileptic
medication for epilepsy will also habitually use illicit
substances.
Reliable epidemiological data linking drug abuse to
seizures are lacking. The quantification of the epilep-
togenicity of illicit drugs is difficult for several rea-
sons.
• Illicit substances are not generally available for
use in controlled trials in humans and even oral
cannabis has not yet been subject to proper clini-
cal trial in epilepsy.
• Their usage often coexists with other potentially
epileptogenic factors such as alcohol dependence,
head injury and other medical and psychiatric dis-
orders.
• Illicit drug use may be more prevalent among
people with epilepsy than the general population,
something that has been suspected (though not al-
ways found2) in other medical disorders such as
diabetes.
• Illegal substance users are less likely to comply
with prescribed medication such as antiepileptic
drugs; this makes comparison of epilepsy control
between users and non-users more difficult.
• Epidemiological data may be distorted by inaccu-
rate reporting of drug doses taken and by the vari-
able purity of available substances.1059–1311/99/080441 + 03 $12.00/0• Personality disorder, low self esteem and a history
of psychological trauma (including sexual abuse)
commonly antedate a drug habit; all are closely
linked to the development of non-epileptic attack
disorder.
Cocaine appears the most epileptogenic of the com-
monly used illicit drugs3, 4 although not consistently
so in all studies5. This powerful stimulant is available
in two major forms: as the often impure hydrochlo-
ride powder inhaled by snorting, and as the almost
pure ‘free base’ (or ‘crack’) ignited for hot fume in-
halation. The route of administration influences the
seizure risk. The danger from snort inhalation of pow-
dered cocaine appears low but the rapid blood level
rises from inhaled ‘crack’, particularly at high dose
(2–5 g), may provoke acute symptomatic seizures
even in those with no previous epilepsy history6.
Status epilepticus has been reported in overdose6, 7.
Young children are at particular risk of seizures if
exposed to crack fumes through passive inhalation8,
and cocaine-induced seizures appear more common
in females6. Associated sleep deprivation exacerbates
the pro-convulsant properties of cocaine. The terato-
genic potential of cocaine gives further concern since
there is evidence of an increased risk of epilepsy
in offspring exposed to cocaine in utero from retro-
spective human studies9 and from prospective animal
data10.
Cocaine may also have important pharmacokinetic
interactions with antiepileptic medication. For ex-
ample, medications blocking sodium channels (car-
bamazepine, lamotrigine and phenytoin) can worsen
the central toxic effects of cocaine, since this is
also through sodium channel blockade11. A benzo-
diazepine (and not phenytoin) is therefore the treat-
ment of choice for cocaine-induced seizures. Con-
versely, inhibition of neuronal dopamine uptake byc© 1999 BEA Trading Ltd
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MDMA). Lancet 1996; 347: 1052.certain antiepileptics (e.g. vigabatrin) offers a surpris-
ing but promising role for anticonvulsants in prevent-
ing effects of cocaine withdrawal12.
Amphetamines are, in theory, antiepileptic13
but, in practice, seizure threshold falls through
arousal and sleep deprivation. This is particu-
larly important for patients with idiopathic gen-
eralized epilepsy, the type most prevalent among
teenagers14. The amphetamine derivative, ecstasy
(3,4-methylenedioxymethamphatamine or MDMA)
is a popular dance drug even though being banned
from the UK in 1977. Its use remains widespread
despite publicity of rare reactions leading to altered
consciousness, seizures15 and sometimes death16. The
cause appears to be an idiosyncratic malignant hy-
perpyrexia with hyponatraemia from water intoxica-
tion17, 18. Whilst the seizure risk from ecstasy in rare
life-threatening situations derives from its metabolic
consequences, for the large majority any seizure risk
is attributable to sleep deprivation. Ritalin, an am-
phetamine derivative prescribed for childhood atten-
tion deficit hyperactivity disorder, has not been re-
ported to influence seizure tendency.
Opiates including pethidine14, diamorphine,
methadone5 and dextrapropoxyphene certainly pro-
voke seizures, especially in large doses administered
rapidly. Patients presenting with first unprovoked
seizures appear three times more likely to have ‘ever
used’ intravenous opiates5. As with cocaine, treatment
of opiate-induced seizures is with benzodiazepines.
Naloxone is contraindicated in this situation since an-
tagonizing the central opiate depression may actually
worsen seizures20.
Cannabis is the best known and most widely used
of the illicit drugs21. It has been advocated as an
antiepileptic treatment on the basis of one retrospec-
tive study5 and isolated case reports22 but it awaits
systematic study. Oral forms are available under li-
cence for controlled trial (e.g. for spasticity in multiple
sclerosis) but its variable bioavailability and the diffi-
culty in making meaningful comparisons to the effects
of smoke inhalation may present problems. The de-
velopment of prescribed inhaled forms may settle the
debate. At present, however, we await evidence for or
against its epileptogenicity23. A cannabis user present-
ing with seizures must therefore be closely questioned
about other more likely epileptogenic culprits24.
The neurological complications of solvent abuse
have not been studied systematically. One small series,
however, did highlight an increased risk of develop-
ing temporal lobe epilepsy following chronic solvent
inhalation25.
In conclusion, several of the illicit drugs have po-
tential to lower seizure threshold and to interact with
antiepileptic medication. Patients with a seizure ten-
dency should certainly be discouraged from usingocaine, amphetamines or opiates. Cannabis is not
ecessarily harmful to seizures and may even be ben-
ficial. In the absence of systematic studies, however,
linicians’ advice to drug users about this aspect of
heir problem must necessarily be based upon opin-
on, anecdote and only a little evidence.
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